Trials / Active Not Recruiting
Active Not RecruitingNCT06966479
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 396 (actual)
- Sponsor
- Upstream Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verekitug | Verekitug subcutaneous injection. |
| DRUG | Placebo | Verekitug matching placebo. |
Timeline
- Start date
- 2025-05-21
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-05-11
- Last updated
- 2026-04-02
Locations
102 sites across 15 countries: United States, Argentina, Bulgaria, Canada, Chile, Czechia, Germany, Italy, Japan, Poland, South Africa, South Korea, Spain, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06966479. Inclusion in this directory is not an endorsement.